Azole resistance in aspergillus: An emerging problem?

Acta Clinica Belgica

Volumn 67, Issue 5, 2012, Pages 322-327

  Vermeulen, E ^a   Cooreman, S ^b   Maertens, J ^a   Jeurissen, A ^b   Lagrou, K ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b GZA Hospitals   (Belgium)

Author keywords

Aspergillosis; Aspergillus; Azole resistance; Drug resistance; Fungal

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; ECHINOCANDIN; ITRACONAZOLE; POSACONAZOLE; PYRROLE DERIVATIVE; VORICONAZOLE;

ARTICLE; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIGER; ASPERGILLUS TERREUS; BELGIUM; HUMAN; INVASIVE ASPERGILLOSIS; NETHERLANDS; NONHUMAN; TREATMENT FAILURE; ANTIFUNGAL RESISTANCE; ASPERGILLOSIS; DRUG EFFECT; HEALTH; INCIDENCE; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; REVIEW;

ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; AZOLES; DRUG RESISTANCE, FUNGAL; HUMANS; INCIDENCE; MICROBIAL SENSITIVITY TESTS; WORLD HEALTH;

EID: 84872037326     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: 10.2143/ACB.67.5.2062684     Document Type: Article

References (49)

1. Enoch DA, Ludlam HA, Brown NM. Invasive fungal infections: A review of epide-miology and management options. J Med Microbiol 2006; 55: 809-818. (Pubitemid 43974685)
2. Maschmeyer G, Haas A, Cornely OA. Invasive aspergillosis: epidemiology, diag-nosis and management in immunocompromised patients. Drugs 2007; 67(11): 1567-1601. (Pubitemid 47267298)
3. Segal BH. Aspergillosis. N Engl J Med 2009; 360(18): 1870-1884.
4. Lass-Flörl C. The changing face of epidemiology of invasive fungal disease in Europe. Mycoses 2009; 52(3): 197-205.
5. Stevens DA, Kan VL, Judson MA, et al. Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis 2000; 30(4): 696-709.
6. Hope WW, Walsh TJ, Denning DW. The invasive and saprophytic syndromes due to Aspergillus spp. Med Mycol 2005; 43 (Suppl 1): S207-S238. (Pubitemid 41038572)
7. Walsh TJ, Anaissie EJ, Denning DW, et al. Infectious Diseases Society of America. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46(3): 327-360. (Pubitemid 351265310)
8. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32(3): 358-366. (Pubitemid 32173620)
9. Meersseman W, Lagrou K, Maertens J, Van Wijngaerden E. Invasive aspergillosis in the intensive care unit. Clin Infect Dis 2007; 45(2): 205-216. (Pubitemid 47044802)
10. Baddley JW. Clinical risk factors for invasive aspergillosis. Med Mycol 2011; 49 (Suppl 1): S7-S12.
11. Bulpa P, Dive A, Sibille Y. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. Eur Respir J 2007; 30(4): 782-800. (Pubitemid 351194841)
12. Mezger M, Einsele H, Loeffler J. Genetic susceptibility to infections with Asper-gillus fumigatus. Crit Rev Microbiol 2010; 36(2): 168-177.
13. von Eiff M, Roos N, Schulten R, et al. Pulmonary aspergillosis: early diagnosis improves survival. Respiration 1995; 62(6): 341-347.
14. Ferreira ME, Colombo AL, Paulsen I, et al. The ergosterol biosynthesis pathway, transporter genes, and azole resistance in Aspergillus fumigatus. Med Mycol. 200; 43 (Suppl 1): S313-S319.
15. Bueid A, Howard SJ, Moore CB, et al. Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009. J Antimicrob Chemother 2010; 65(10): 2116-2118.
16. Jeurissen A, Cooreman S, Van Kerckhoven W, et al. Invasive pulmonary aspergil-losis due to a multi-azole resistant Aspergillus fumigatus. Acta Clinica Belgica 2011, in press.
17. Howard SJ, Cerar D, Anderson MJ, et al. Frequency and evolution of Azole resis-tance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis 2009; 15(7): 1068-1076.
18. Verweij PE, Mellado E, Melchers WJ. Multiple-triazole-resistant aspergillosis. N Engl J Med 2007; 356(14): 1481-1483.
19. Verweij PE, Howard SJ, Melchers WJ, Denning DW. Azole-resistance in Aspergil-lus: proposed nomenclature and breakpoints. Drug Resist Updat 2009; 12(6): 141-147.
20. van der Linden JW, Warris A, van der Meer JW, Bresters D, Melchers WJ, Ver-weij PE. Azole-resistant invasive aspergillosis. Ned Tijdschr Geneeskd 2009; 153: A765.
21. Hong SB, Shin HD, Hong J, et al. New taxa of Neosartorya and Aspergillus in Aspergillus section Fumigati. Antonie Van Leeuwenhoek 2008; 93(1-2): 87-98.
22. alajee SA, Kano R, Baddley JW, et al. Molecular identification of Aspergillus species collected for the Transplant-Associated Infection Surveillance Network. J Clin Microbiol 2009; 47(10): 3138-3141.
23. Van Der Linden JW, Warris A, Verweij PE. Aspergillus species intrinsically resis-tant to antifungal agents. Med Mycol 2011; 49 (Suppl 1): S82-S89.
24. Symoens F, Haase G, Pihet M, et al. Unusual Aspergillus species in patients with cystic fibrosis. Med Mycol 2010; 48 (Suppl 1): S10-S16.
25. Vinh DC, Shea YR, Jones PA, Freeman AF, Zelazny A, Holland SM. Chronic inva-sive aspergillosis caused by Aspergillus viridinutans. Emerg Infect Dis 2009; 15(8): 1292-1294.
26. Coelho D, Silva S, Vale-Silva LS, et al. Aspergillus viridinutans: An agent of adult chronic invasive aspergillosis. Med Mycol 2011; Feb 7 [Epub ahead of print].
27. Hope WW, Walsh TJ, Denning DW. Laboratory diagnosis of invasive aspergillosis. Lancet Infect Dis (2005); 5(10): 609-622. (Pubitemid 41383906)
28. Torres HA, Rivero GA, Lewis RE, Hachem R, Raad II, Kontoyiannis DP. Aspergil-losis caused by non-fumigatus Aspergillus species: risk factors and in vitro sus-ceptibility compared with Aspergillus fumigatus. Diagn Microbiol Infect Dis 2003; 46(1): 25-28. (Pubitemid 36556017)
29. Lionakis MS, Lewis RE, Torres HA, Albert ND, Raad II, Kontoyiannis DP. Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli. Diagn Micro-biol Infect Dis 2005; 52(1): 15-20. (Pubitemid 40692735)
30. Chamilos G, Kontoyiannis DP. Update on antifungal drug resistance mecha-nisms of Aspergillus fumigatus. Drug Resist Updat 2005; 8(6): 344-358. (Pubitemid 43358058)
31. Espinel-Ingroff A, Diekema DJ, Fothergill A, et al. Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). J Clin Microbiol 2010; 48(9): 3251-3257.
32. Hachem RY, Kontoyiannis DP, Boktour MR, Afif C, Cooksley C, Bodey GP, Chatzinikolaou I, Perego C, Kantarjian HM, Raad II. Aspergillus terreus: An emerging amphotericin B-resistant opportunistic mold in patients with hema-tologic malignancies. Cancer 2004; 101(7): 1594-600. (Pubitemid 39318906)
33. Rüping MJ, Gerlach S, Fischer G, et al. Environmental and clinical epidemiology of Aspergillus terreus: data from a prospective surveillance study. J Hosp Infect 2011; Mar 24 [Epub ahead of print].
34. Mortensen KL, Mellado E, Lass-Flörl C, Rodriguez-Tudela JL, Johansen HK, Arendrup MC. Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain. Antimicrob Agents Chemother 2010; 54(11): 4545-4549.
35. Lass-Flörl C, Rath P, Niederwieser D, et al. Aspergillus terreus infections in hae-matological malignancies: molecular epidemiology suggests association with in-hospital plants. J Hosp Infect 2000; 46(1): 31-35.
36. Lass-Flörl C, Kofler G, Kropshofer G, et al. In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergil-losis. J Antimicrob Chemother 1998; 42(4): 497-502. (Pubitemid 28473010)
37. Howard SJ, Arendrup MC. Acquired antifungal drug resistance in Aspergillus fumigatus: epidemiology and detection. Med Mycol 2011; 49 (Suppl 1): S90- S95.
38. Verweij PE, Snelders E, Kema GH, Mellado E, Melchers WJ. Azole resistance in Aspergillus fumigatus: A side-effect of environmental fungicide use? Lancet Infect Dis 2009; 9(12): 789-795.
39. Snelders E, van der Lee HA, Kuijpers J, Rijs AJ, Varga J, Samson RA, Mellado E, Donders AR, Melchers WJ, Verweij PE. Emergence of azole resistance in Aspergil-lus fumigatus and spread of a single resistance mechanism. PLoS Med 2008; 5(11): e219.
40. Lagrou K, De Vleeschouwer J, Meerseman W, et al. Triazole resistance among 229 clinical Aspergillus fumigatus isolates. Proceedings of the 3rd Advances Against Aspergillosis Meeting, Miami, FL, USA; Jan 16-19, 2008. Abstract 33.
41. Mellado E, Garcia-Effron G, Alcázar-Fuoli L, et al. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob Agents Chemother 2007; 51(6): 1897-904. (Pubitemid 46903071)
42. Rajendran R, Mowat E, McCulloch E, et al. Azole resistance of Aspergillus fumi-gatus biofilms is partly associated with efflux pump activity. Antimicrob Agents Chemother 2011; 55(5): 2092-2097.
43. Howard SJ, Arendrup MC. Acquired antifungal drug resistance in Aspergillus fumigatus: epidemiology and detection. Med Mycol 2011; 49 Suppl 1: S90-S95.
44. Alanio A, Sitterlé E, Liance M, Farrugia C, Foulet F, Botterel F, Hicheri Y, Cordonnier C, Costa JM, Bretagne S. Low prevalence of resistance to azoles in Aspergillus fumigatus in a French cohort of patients treated for haematological malignancies. J Antimicrob Chemother 2011; 66(2): 371-374.
45. Andaluz N, Zuccarello M. Multidrug-resistant, progressive, invasive diffuse spi-nal aspergillosis: case report and review of the literature. J Neurosurg Sci 2008; 52(2): 49-53.
46. Arendrup MC, Mavridou E, Mortensen KL, Snelders E, Frimodt-Møller N, Khan H, Melchers WJ, Verweij PE. Development of azole resistance in Aspergillus fumig-atus during azole therapy associated with change in virulence. PLoS One 2010; 5(4): e10080.
47. uipers S, Brüggemann RJ, de Sévaux RG, et al. Failure of posaconazole therapy in a renal transplant patient with invasive aspergillosis due to Aspergillus fumigatus with attenuated susceptibility to posaconazole. Antimicrob Agents Chemother 2011; Apr 18 [Epub ahead of print].
48. Howard SJ, Webster I, Moore CB, Gardiner RE, Park S, Perlin DS, Denning DW. Multi-azole resistance in Aspergillus fumigatus. Int J Antimicrob Agents 2006; 28(5): 450-453. (Pubitemid 44740492)
49. Denning DW, Park S, Lass-Florl C, Fraczek MG, Kirwan M, Gore R, Smith J, Bueid A, Moore CB, Bowyer P, Perlin DS. High-frequency triazole resistance found In nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease. Clin Infect Dis 2011; 52(9): 1123-1129.